Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 4/20 | 0.57 |
| ▸ | GRPR | P30550 | 10/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neurokinin B SCHEMBL29440672 | 0.94 | GRPR (0.59) | GRPR | |
| Neurokinin B SCHEMBL29390479 | 0.94 | GRPR (0.59) | GRPR | |
| SCHEMBL29406603 | 0.84 | CTSB (0.54) | TACR3 | |
| Neurokinin A SCHEMBL29374005 | 0.83 | PTH1R (0.62) | — | |
| Neurokinin A SCHEMBL29374084 | 0.83 | PTH1R (0.62) | — | |
| Neurokinin B SCHEMBL29372314 | 0.82 | GRPR (0.53) | GRPR | |
| SCHEMBL29569383 | 0.82 | OPRM1 (0.57) | GRPR | |
| Senktide SCHEMBL5238634 | 0.81 | TACR3 (0.82) | TACR3 | |
| SCHEMBL29678561 | 0.81 | CCKAR (0.51) | — | |
| SCHEMBL29972794 | 0.81 | TACR3 (0.56) | TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262267-A1 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | BONAFIDE HEALTH LLC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20240408165-A1 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | BONAFIDE HEALTH, LLC | 2024-12-12 | — | — | US | disclosed |
| EP-4429687-A1 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | Bonafide Health, LLC (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-4431512-A1 | NOVEL DUAL NK-1/NK-3 RECEPTOR ANTAGONISTS | Bayer Consumer Care AG (CH) | 2024-09-18 | — | — | EP | disclosed |
| US-12070482-B2 | Curcumin compositions and methods of use as an NK3 antagonist | BONAFIDE HEALTH, LLC (US) | 2024-08-27 | — | — | US | disclosed |
| US-11857594-B2 | Curcumin compositions and methods of use as an NK3 antagonist | JDS THERAPEUTICS, LLC (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230414696-A1 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | JDS THERAPEUTICS, LLC | 2023-12-28 | — | — | US | disclosed |
| US-11779627-B1 | Curcumin compositions and methods of use as an NK3 antagonist | JDS THERAPEUTICS, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023091262-A1 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | JDS THERAPEUTICS, LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230149499-A1 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | BONAFIDE HEALTH, LLC | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262267-A1 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | TAC3, PTGER3, TRPV3 | TACR3 27/4885GRPR 34/4885 |
| US-20230149499-A1 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | TAC3, PTGER3, TRPV3 | TACR3 27/4885GRPR 34/4885 |
| US-11779627-B1 | Curcumin compositions and methods of use as an NK3 antagonist | TAC3, PTGER3, TRPV3 | TACR3 27/4885GRPR 34/4885 |
| US-11857594-B2 | Curcumin compositions and methods of use as an NK3 antagonist | TAC3, PTGER3, TRPV3 | TACR3 27/4885GRPR 34/4885 |
| US-12070482-B2 | Curcumin compositions and methods of use as an NK3 antagonist | TAC3, PTGER3, TRPV3 | TACR3 27/4885GRPR 34/4885 |
| US-20230414696-A1 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | TAC3, PTGER3, TRPV3 | TACR3 27/4885GRPR 34/4885 |
| US-20240408165-A1 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | TAC3, PTGER3, TRPV3 | TACR3 27/4885GRPR 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.